PMID- 17652944
OWN - NLM
STAT- MEDLINE
DCOM- 20070829
LR  - 20181201
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 71
IP  - 3-4
DP  - 2006
TI  - Short schedule of cisplatin and vinorelbine: a dose-finding study in 
      non-small-cell lung cancer.
PG  - 229-36
AB  - OBJECTIVES: A dose-finding study of a new cisplatin/vinorelbine schedule was done 
      to increase activity of the combination, and improve compliance of non-small-cell 
      lung cancer PATIENTS. METHODS: Beginning with cisplatin 40 mg/m(2) on days 1, 2 
      and vinorelbine 20 mg/m(2) on days 1, 3, increasing dose levels up to the maximum 
      tolerated dose (MTD) were tested in a series of 6-patient cohorts. If 3 of 6 
      patients experienced dose-limiting toxicity in the first 3 cycles, the previous 
      dose was considered the recommended dose (RD). Once the MTD was reached, 
      granulocyte-colony-stimulating factor was prophylactically added to the treatment 
      of a new patient cohort to improve the therapeutic ratio. RESULTS: We enrolled 35 
      stage IIIA/B or IV patients between August 2001 and February 2002. The RD was 
      cisplatin 45 mg/m(2) and vinorelbine 25 mg/m(2), with relative dose intensities 
      (RDIs) of 95 and 97%, respectively, and an actual received dose intensity (ARDI) 
      of 28.62 and 16.07 mg/m(2)/week, respectively. Overall grade 3-4 toxicities were: 
      neutropenia (71%), febrile neutropenia (25%), anemia (8%), and constipation 
      (17%). The overall response rate was 64.3% (CI: 44.1-81.4%). CONCLUSIONS: ARDI 
      and RDI of our modified cisplatin/vinorelbine regimen were not inferior to those 
      of conventional weekly schedules; its acceptable toxicity profile and 
      manageability may justify its use in clinical practice.
FAU - Zucali, Paolo Andrea
AU  - Zucali PA
AD  - Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, 
      Rozzano, Milan, Italy. Paolo.Zucali@humanitas.it
FAU - Soto Parra, Hector Jose
AU  - Soto Parra HJ
FAU - Cavina, Raffaele
AU  - Cavina R
FAU - Campagnoli, Elisabetta
AU  - Campagnoli E
FAU - Latteri, Fiorenza
AU  - Latteri F
FAU - De Vincenzo, Fabio
AU  - De Vincenzo F
FAU - Ceresoli, Giovanni Luca
AU  - Ceresoli GL
FAU - Fazio, Maria
AU  - Fazio M
FAU - Alloisio, Marco
AU  - Alloisio M
FAU - Santoro, Armando
AU  - Santoro A
LA  - eng
PT  - Journal Article
DEP - 20070723
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 5V9KLZ54CY (Vinblastine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Pilot Projects
MH  - Vinblastine/administration & dosage/analogs & derivatives
MH  - Vinorelbine
EDAT- 2007/07/27 09:00
MHDA- 2007/08/30 09:00
CRDT- 2007/07/27 09:00
PHST- 2006/07/11 00:00 [received]
PHST- 2007/01/13 00:00 [accepted]
PHST- 2007/07/27 09:00 [pubmed]
PHST- 2007/08/30 09:00 [medline]
PHST- 2007/07/27 09:00 [entrez]
AID - 000106427 [pii]
AID - 10.1159/000106427 [doi]
PST - ppublish
SO  - Oncology. 2006;71(3-4):229-36. doi: 10.1159/000106427. Epub 2007 Jul 23.